ENT Updates
Experimental Study

Cetuximab alone has a dose-dependent antitumor effect in oral cavity cancer cells: an in vitro study

1.

Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Celal Bayar University, Manisa, Turkey

2.

Department of Basic Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey

3.

Department of Preventive Oncology, Institute of Oncology, Dokuz Eylül University, Izmir, Turkey

ENT Updates 2016; 6: 105-109
DOI: 10.2399/jmu.2016003005
Read: 990 Downloads: 667 Published: 01 February 2021

Objective: To evaluate the antitumor effect of cetuximab as a single agent for the treatment of oral cavity cancers and to clarify the dosedependent growth inhibitory effect in oral cavity squamous cell carcinoma cell line (OCSCCCL).

Methods: The OCSCCCL (UPCI-SCC131) were cultured and continuously monitored using the xCELLigence RTCA SP instrument. Thereafter, they were divided into seven groups as: (i) negative control: medium+OCSCCCL, (ii) positive control: medium+OCSCCCL+cisplatin 10 μM/ml, (iii) medium+OCSCCCL+cetuximab 25 μg/ml, (iv) medium+OCSCCCL+cetuximab 50 μg/ml, (v) medium+OCSCCCL+ cetuximab 100 μg/ml, (vi) medium+OCSCCCL+cetuximab 200 μg/ml, (vii) medium+OCSCCCL+cetuximab 400 μg/ml. The cell index and viability were statistically analyzed and compared between groups.

Results: The distribution of cell index (mean value) and percentage of viability in groups were as follows: (i) 2.66 (100%), (ii) 0.17 (6.08%), (iii) 2.28 (85.71%), (iv) 2.31 (86.84%), (v) 1.92 (72.18%), (vi) 1.79 (67.29%), (vii) 0.28 (10.53%). The change trend in drug concentration was statistically different in all study groups to which cetuximab was administered (Pillai’s trace; p<0.0001). The antitumor effect of cetuximab was initially detected at a dose of 100 μg/mL, when compared with negative control (p=0.01). However, a dose of 400 μg/mL was required in order to have a statistically similar antitumor effect of cisplatin at a dose of 10 μM.

Conclusion: Cetuximab alone is a potentially effective chemotherapeutic agent and has a concentration-dependent growth inhibitory effect in OCSCCCL. The antitumor activity of cetuximab was initially detected at a dose of 100 μg/mL. However, significant antitumor effect was determined at a dose of 400 μg/mL.


Tek bir ajan olarak setuksimab oral kavite kanser hücrelerinde doza bağımlı etkiye sahiptir: Bir in vitro çalışma

Amaç: Tek bir ajan olarak setuksimabın oral kavite kanserlerinin tedavisindeki antitümöral etkisini de¤erlendirmek ve oral kavite yassı epitel hücreli karsinom dizininde (OCSCCCL) doza bağımlı büyümeyi inhibe etme etkisini açıklığa kavuşturmak.

Yöntem: OCSCCCL (UPCI-SCC131) kültürü elde edildi ve xCELLigence RTCA SP cihaz› kullan›larak izlendi. Daha sonra yedi gruba bölüştürüldü: (i) negatif kontrol: besiyeri+OCSCCCL, (ii) pozitif kontrol: besiyeri+OCSCCCL+sisplatin 10 μM/ml, (iii) besiyeri+OCSCCCL+setuksimab 25 μg/ml, (iv) besiyeri+OCSCCCL+setuksimab 50 μg/ml, (v) besiyeri+OCSCCCL+setuksimab 100 μg/ml, (vi) besiyeri+OCSCCCL+setuksimab 200 μg/ml, (vii) besiyeri+OCSCCCL+setuksimab 400 μg/ml. Hücre indeksi ve viyabilite istatistiksel açıdan incelendi ve gruplar arasında karşılaştırıldı.

Bulgular: Hücre indeksinin (ortalama değer) ve viyabilite yüzdesinin dağılımı şu şekilde bulundu: (i) 2.66 (%100), (ii) 0.17 (%6.08), (iii) 2.28 (%85.71), (iv) 2.31 (%86.84), (v) 1.92 (%72.18), (vi) 1.79 (%67.29), (vii) 0.28 (%10.53). ilaç konsantrasyonundaki değişiklik eğilimi setuksimabın uygulandığı çalışma gruplarının tümünde istatistiksel açıdan anlamlı idi (Pillai trasesi; p<0.0001). Negatif kontrolle karşılaştırıldığında setuksimabın antitümöral etkisi ilk olarak 100 μg/mL dozda saptandı (p=0.01). Ancak 10 μM sisplatinin etkisine istatistiksel aç›dan benzer antitümöral etki için 400 μg/mL doz gerekliydi.

Sonuç: Tek başlığına setuksimab potansiyel olarak etkili bir kemoterapötik ajan olup OCSCCL’de konsantrasyona bağımlı büyümeyi inhibe edici etkiye sahiptir. Setuksimabın antitümöral aktivitesi başlangıçta 100 μg/mL dozda saptanmıştır. Ancak 400 μg/mL dozda anlamlı bir antitümöral etki belirlenmiştir.

Files
EISSN 2149-6498